The pathogenetic impact of this variant is well established in a murine bone marrow transplantation model in which T618I is sufficient to generate a lethal myeloproliferative disorder with neutrophilic expansion sensitive to JAK1/2 inhibition [25]. Here, JAK1 is linked to myeloproliferative disorder.